Alexion inks deal to acquire Achillion for $930M upfront


Alexion has struck a deal to buy Achillion for $930M. The takeover will give Alexion two clinical-phase medicines in development in complement alternative pathway-mediated rare diseases.


Achillion is focused on the development of oral small-molecule factor D inhibitors in indications such as paroxysmal nocturnal hemoglobinuria (PNH) and C3 glomerulopathy. Alexion has grown into a substantial business by treating complement-mediated diseases such as PNH and thinks there are enough differences in their approaches to make the acquisition of Achillion worthwhile.


Read the full article at…


Comments are closed.

More in Ashton Tweed Connection, News & Trends
Novartis, Microsoft ink 5-year AI alliance

Novartis announced a five-year partnership with Microsoft in a bet that the tech company can help it make better sense...